Alirocumab is a human monoclonal antibody that binds PCSK9, preventing PCSK9 from binding LDL receptors on liver cells. This keeps more LDL receptors available to clear LDL cholesterol from the blood. It is studied in hypercholesterolemia.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Praluent, REGN-727, SAR-236553
Drug type
Monoclonal antibody
Targets
proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor (LDLR) (binding partner it blocks)
Mechanism
Inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9)
Pathways
LDL receptor degradation in hepatocytes, LDL cholesterol clearance
From the indications section of the FDA label (version of Jul 16, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.